Compare AbCellera Biologics Inc (ABCL) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Hormel Foods Corp — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while Hormel Foods Corp trades at $24.61 (market cap $13.59B). The key difference: Hormel Foods Corp is far larger — about 5.8× AbCellera Biologics Inc's market cap, and Hormel Foods Corp pays a 4.74% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HRL | |
|---|---|---|
Market Cap | $2.35B | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $31.54 |
52-Week Low | $2.78 | $19.74 |
Enterprise Value | $1.99B | $15.59B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Hormel Foods (HRL) trades at $24.70, down 1.2% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock has consistently beaten earnings estimates in recent quarters, though net income margin has compressed to 3.82%. Recent corporate actions include steady $0.29 dividends, while the company sold its Brazilian Ceratti operations to sharpen international focus. Analyst consensus price target is $25.00, slightly above current levels.
HRL offers a stable dividend profile as a Dividend King but faces margin pressure and modest growth. Near-term upside appears limited given current valuation and mixed analyst ratings. Key risks include input cost inflation and competitive pressures in the consumer staples sector. The stock presents a defensive income opportunity rather than significant capital appreciation potential in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
